{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":26,"n_cols":5,"rows_kept":26,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[17,2,17,3],[18,2,18,3],[21,2,21,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910483036503321"]
[null,null,"Autore",null,"Holvoet Paul"]
[null,null,"Titolo",null,"Non-coding RNAs at the cross-road of cardiometabolic diseases and cancer / / Paul Holvoet"]
[null,null,"Pubbl/distr/stampa",null,"Cham, Switzerland : , : Springer, , [2021]"]
[{"$nulls":4},"©2021"]
[null,null,"ISBN",null,"3-030-68844-5"]
[null,null,"Descrizione fisica",null,"1 online resource (xxx, 265 pages) : illustrations"]
[null,null,"Disciplina",null,"572.88"]
[null,null,"Soggetti",null,"Non-coding RNA"]
[{"$nulls":4},"Cardiovascular system - Diseases - Molecular aspects"]
[{"$nulls":4},"Metabolism - Disorders - Molecular aspects"]
[{"$nulls":4},"Cancer - Genetic aspects"]
[{"$nulls":4},"Càncer"]
[{"$nulls":4},"Malalties cardiovasculars"]
[{"$nulls":4},"Trastorns del metabolisme"]
[{"$nulls":4},"Genètica molecular humana"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Intro -- Preface -- Acknowledgments -- Introduction -- The Move Towards Cellular Risk Markers -- Why Non-coding RNA? -- Objectives -- Approach -- Take Home Message -- References -- Contents -- Abbreviations -- 1 Biogenesis and Modes of Action of miRs and Circular and Long Non-coding RNAs -- 1.1 MiRs -- 1.1.1 Biogenesis of miRs -- 1.1.2 MiR Modes of Action -- 1.1.3 Naming of miRs -- 1.1.4 Useful Resources on miRs -- 1.2 Circular RNAs -- 1.2.1 Biogenesis of Circular RNAs -- 1.2.2 Circular RNAs Modes of Action -- 1.2.3 Useful Resources on Circ-RNAs -- 1.3 lncRNAs -- 1.3.1 Biogenesis of lncRNAs -- 1.3.2 Modes of Action of lncRNAs -- 1.4 piRs -- 1.4.1 Biogenesis of piRs -- 1.4.2 Modes of Action of piRs -- 1.4.3 Useful Resources on piRs -- References -- 2 Non-coding RNAs Related to Obesity -- 2.1 Mechanisms in White Adipogenesis -- 2.1.1 Role of Non-coding RNAs in White Adipogenesis -- 2.2 Inflammation and Insulin Resistance in Obese White Adipose Tissue -- 2.2.1 Role of Non-coding RNAs in Inflammation and Insulin Resistance "]
[{"$nulls":4},"in Obese White Adipose Tissue -- 2.3 Mechanisms in Brown Adipogenesis and Thermogenesis -- 2.3.1 Role of Non-coding RNAs in Brown Adipogenesis and Thermogenesis -- 2.4 Mechanisms in Browning of White Adipose Tissues -- 2.4.1 Role of Non-coding RNAs in Browning of White Adipose Tissue -- 2.5 Leptin and Insulin in the Hypothalamus -- 2.5.1 Non-coding RNAs Related to Leptin and Insulin in the Hypothalamus -- References -- 3 Non-coding RNAS Related to Type 2 Diabetes -- 3.1 Mechanisms in β Cell Maturation -- 3.1.1 Non-coding RNAs Related to β Cell Maturation -- 3.2 Mechanisms in Insulin Signaling in the Pancreas -- 3.2.1 Non-coding RNAs in Insulin Signaling in Type 2 Diabetes -- 3.3 Inflammation in the Pancreas, Insulin Resistance, and Type 2 Diabetes."]
[{"$nulls":4},"3.3.1 Non-coding RNAs Related to Inflammation in the Pancreas, with Insulin Resistance and Type 2 Diabetes -- References -- 4 Non-coding RNAs Related to Lipid Metabolism and Non-alcoholic Fatty Liver Disease -- 4.1 Cholesterol and Lipids in the Liver -- 4.1.1 Non-coding RNAs and Cholesterol in the Liver -- 4.2 Fatty Acids and Triglycerides -- 4.2.1 Non-coding RNAs and Fatty Acids and Triglycerides -- 4.3 Non-alcoholic Fatty Liver Disease -- 4.3.1 Non-coding RNAs Related to Non-alcoholic Fatty Liver Disease -- References -- 5 Non-coding RNAs Related to Atherosclerosis -- 5.1 Endothelial Injury, Inflammation, and Apoptosis -- 5.1.1 Non-coding RNAs in Endothelial Injury, Inflammation, and Apoptosis -- 5.2 Fibroproliferative Remodeling and Plaque Destabilization -- 5.2.1 Non-coding RNAs in Fibroproliferative Remodeling and Plaque Destabilization -- References -- 6 Non-coding RNAs in Cardiomyopathy and Heart Failure -- 6.1 Mechanisms in Cardiomyopathy and Heart Failure -- 6.2 Non-coding RNAs in Cardiomyopathy and Heart Failure -- 6.2.1 Non-coding RNAs in Cardiac Hypertrophy -- 6.2.2 Non-coding RNAs in Cardiac Fibrosis and ECM Deposition -- 6.2.3 Non-coding RNAs in Cardiac Inflammation -- 6.2.4 Non-coding RNAs in Cardiac Angiogenesis -- 6.2.5 Non-coding RNAs in Cardiac Apoptosis -- 6.3 Metabolic Syndrome: The Link Between Metabolic and Cardiovascular Diseases -- 6.3.1 Definition of Metabolic Syndrome -- 6.3.2 Oxidative Stress and Metabolic Syndrome -- 6.3.3 Metabolic Syndrome and Cardiovascular Risk -- 6.3.4 Non-coding RNAs and Metabolic Syndrome Components -- References -- 7 Non-coding RNAs Related to Cardiometabolic Diseases and Associated to Cancer -- 7.1 Mechanisms of Cancer Progression -- 7.1.1 Induction of Stemness -- 7.1.2 Induction of EMT -- 7.1.3 Induction of Insulin Sensitized State, Cancer Cell Proliferation, and Protection Against Apoptosis."]
[{"$nulls":4},"7.1.4 Induction of Glycolysis -- 7.1.5 Induction of Angiogenesis -- 7.1.6 Repression of Anti-tumor Immunity and Apoptosis -- 7.1.7 Cancer Cell Proliferation -- 7.1.8 EGFR Signaling and Cancer Progression -- 7.1.9 BMI1 and EZH2 in Cancer Progression -- 7.2 Non-coding RNAs Related to Metabolic and Cardiovascular Diseases Are also Involved in Cancer Progression -- 7.3 Comparison of the Role of Non-coding RNAs in Cardiometabolic Diseases and Cancer -- References -- 8 Regulation of Non-coding RNAs in Cardiometabolic Tissues and Tumors -- 8.1 Regulation of miRs -- 8.1.1 Hypoxia -- 8.1.2 Glucose -- 8.1.3 Oxidative Stress -- 8.1.4 Inflammation -- 8.1.5 TGF-β -- 8.1.6 MYC -- 8.1.7 Overview -- 8.2 Differences in miR-Profiles in Cardiometabolic Tissues and Tumors May be Due to the Typical Action of lncRNAs and circ-RNAs in Tumors -- 8.3 Action of piRs Particularly in Tumors -- References -- 9 Communication Between Tumor-Adjacent Tissues and Tumors with Emphasis on Role of Inflammatory Cells -- 9.1 Exchange of miR-Enriched Microvesicles -- 9.2 MiR-155 as a Link Between M1 Macrophage-Mediated "]
[{"$nulls":4},"Inflammation in Tumor-Adjacent Tissue and Tumor Growth and Metastasis -- References -- 10 The Impact of Non-coding RNA Networks on Disease Comorbidity: Cardiometabolic Diseases, Inflammatory Diseases, and Cancer -- 10.1 Identification of Non-coding RNAs at Cross-Road of Metabolic and Cardiovascular Diseases -- 10.2 Many Non-coding RNAs at Cross-Road of Metabolic and Cardiovascular Diseases are also Related to Inflammatory Diseases -- 10.3 Differences Between Non-coding RNAs in Cardiometabolic Tissues and Tumors -- 10.4 Expected Technical Developments Underlying the Use of Non-coding RNAs as Biomarkers -- 10.5 The Need for Measuring Fluctuation of Non-coding RNAs -- References."]